Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 6/20 | 0.51 |
| ▸ | PDE4A | P27815 | 4/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383074 | 0.85 | NR3C2 (0.57) | NR3C2IDO1NPC1RAB9A | |
| SCHEMBL1380387 | 0.84 | NR3C2 (0.56) | NR3C2ENPP1RAB9A | |
| SCHEMBL2048793 | 0.83 | NR3C2 (0.61) | NR3C2RAB9A | |
| SCHEMBL1378097 | 0.83 | NR3C2 (0.57) | NR3C2RAB9A | |
| SCHEMBL4639952 | 0.83 | NOTUM (0.44) | — | |
| SCHEMBL1380916 | 0.82 | NR3C2 (0.53) | NR3C2RAB9A | |
| SCHEMBL1381274 | 0.82 | NR3C2 (0.56) | NR3C2RAB9A | |
| SCHEMBL1381078 | 0.82 | NR3C2 (0.58) | NR3C2PDE4ANPC1RAB9A | |
| SCHEMBL2027252 | 0.81 | NR3C2 (0.55) | NR3C2RAB9A | |
| SCHEMBL2026807 | 0.81 | NR3C2 (0.59) | NR3C2IDO1NPC1RAB9AMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4703649-B2 | — | — | 2011-06-15 | — | — | JP | claimed |
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | EXELIXIS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | NR3C2 119/4885PDE4A 383/4885PDE4B 459/4885 |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | NCOA1, NCOA2, NCOA3 | NR3C2 10/4885PDE4A 983/4885PDE4B 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.